Yoon Seokho Bryan 4

4 · Nightstar Therapeutics plc · Filed Jun 7, 2019

Form 4

Period: 2019-06-06

General Counsel and Secretary

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2019-06-07$2.72/sh−160,000$435,200→ 0 total
Exercise: $22.78Exp: 2027-11-05→ Ordinary Shares (160,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-06-07$10.76/sh−85,100$915,676→ 0 total
Exercise: $14.74Exp: 2029-01-21→ Ordinary Shares (85,100 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-06-07$11.26/sh−15,000$168,900→ 0 total
Exercise: $14.24Exp: 2028-01-30→ Ordinary Shares (15,000 underlying)

Footnotes (3)

[F1]In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of Nightstar Therapeutics plc (the "Issuer") on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price.
[F2]The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
[F3]Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price.

Documents

1 file